Dr. Reddy’s Laboratories announced today that is has launched Docetaxel Injection USP 20 mg/mL and 80 mg/4 mL a therapeutic equivalent generic version of TAXOTERE (docetaxel Injection) in the US market on November 21, 2014. Dr. Reddy’s ANDA is approved by the United States Food & Drug Administration (USFDA).
The TAXOTERE brand and generic has US sales of approximately $218 Million MAT for the most recent twelve months ending in September 2014 according to IMS Health*.
Dr. Reddy’s Docetaxel Injection USP, 20 mg/mL and 80 mg/4 mL are available as a single dose, one vial formulation that does NOT require a prior dilution with a diluent and is ready to add to the Intravenous Infusion solution.